|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
Rajeev Nannapaneni
|
|
gptkbp:country
|
gptkb:India
|
|
gptkbp:focusArea
|
gptkb:hepatitis_C
cardiology
oncology
gastroenterology
crop health
|
|
gptkbp:founded
|
1981
|
|
gptkbp:founder
|
V.C. Nannapaneni
|
|
gptkbp:headquarters_location
|
gptkb:Hyderabad
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Natco Pharma
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
INE987B01026
|
|
gptkbp:market
|
gptkb:Asia
gptkb:Canada
gptkb:Europe
gptkb:India
gptkb:United_States
|
|
gptkbp:notableProduct
|
generic version of Sorafenib
generic version of Tamiflu
generic version of Revlimid
|
|
gptkbp:numberOfEmployees
|
over 5000
|
|
gptkbp:parentCompany
|
Natco Trust (major shareholder)
|
|
gptkbp:products
|
active pharmaceutical ingredients
generic medicines
crop health sciences
|
|
gptkbp:revenue
|
INR 3,982 crore
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:NSE
BSE
|
|
gptkbp:subsidiary
|
Natco Pharma (Canada) Inc.
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.natcopharma.co.in/
|
|
gptkbp:bfsParent
|
gptkb:NIFTY_Pharma
gptkb:VESTANAT
|
|
gptkbp:bfsLayer
|
8
|